News

Sage Bionetworks and Celgene Corporation launch Journey PRO, a mobile health research study to improve lives of patients living with chronic anemia

August 14, 2017

Sage Bionetworks and Celgene Corporation launch Journey PRO, a mobile health research study to improve lives of patients living with chronic anemia

Sage Bionetworks and Celgene Corporation announce the launch of Journey PRO, a mobile health research study to improve the lives of Chronic Anemia Patients

Seattle, WA – Sage Bionetworks, a non-profit biomedical research accelerator, together with Celgene Corporation (NASDAQ: CELG) today announced the launch of Journey PRO, a mobile health research study designed to improve the understanding of disease burden on people living with chronic anemia due to myelodysplastic syndromes (MDS), myelofibrosis, and beta-thalassemia.

This study uses mobile and wearable technologies to quantify the daily burden of chronic anemia on patients living with these diseases. The study utilizes the Apple ResearchKit framework to collect data from participants using surveys, neurological self-assessments using the BrainBaseline cognitive testing software from Digital Artifacts, health data collected from the iPhone HealthKit, and fitness tracking wearables, among others. By following participants using these quantitative assessments, we aim to develop a tool to evaluate the efficacy of new treatments for reducing the impact of these diseases on patients. “Understanding the impact of disease on daily living is important to patients as well as researchers,” said Lara Mangravite, President of Sage Bionetworks and PI of the study. “For this reason, Journey PRO will provide direct and immediate information back to research participants to help them manage their health.”  Read the full release.